BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 11288443)

  • 1. [Measles, mumps, rubella: important health risks].
    Rev Infirm; 2000 Oct; (64):13-5. PubMed ID: 11288443
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Laws HJ; Calaminus G; Göbel U
    Cancer; 2005 Apr; 103(8):1759; author reply 1760. PubMed ID: 15717299
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Fioredda F; Giacchino M; Castagnola E
    Cancer; 2005 Apr; 103(8):1758-9; author reply 1760. PubMed ID: 15717298
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful seroresponses to measles and rubella following aerosolized Triviraten vaccine, but poor response to aerosolized mumps (Rubini) component: comparisons with injected MMR.
    Diaz-Ortega JL; Bennett JV; Castaneda D; Vieyra JR; Valdespino-Gomez JL; de Castro JF
    Vaccine; 2010 Jan; 28(3):692-8. PubMed ID: 19861187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMR vaccination: new thought.
    Deshmukh V
    Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
    Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M; Hafizi M; Moghni M; Kheiri S; Esteghamati A; Sarikhani S
    East Afr J Public Health; 2011 Jun; 8(2):88-91. PubMed ID: 22066292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK; Chiu YL; Wilkin T
    AIDS Patient Care STDS; 2015 Sep; 29(9):461-4. PubMed ID: 26153909
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. London's catch-up vaccination campaign against measles, mumps, and rubella reaches less than a quarter of children who were unvaccinated.
    Hitchen L
    BMJ; 2008 Sep; 337():a1797. PubMed ID: 18815174
    [No Abstract]   [Full Text] [Related]  

  • 18. Measles, mumps, and rubella (MMR) vaccination: an update.
    Koth SM; Descourouez JL; Hayney MS
    J Am Pharm Assoc (2003); 2014; 54(3):309-10; 312. PubMed ID: 24816358
    [No Abstract]   [Full Text] [Related]  

  • 19. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
    Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.